ICON (NASDAQ:ICLR), a global provider of outsourced development
services to the pharmaceutical, biotechnology and medical device
industries, announced that at its Extraordinary General Meeting held
in Dublin today, all resolutions put to the meeting were passed. These
included a proposal to issue one new ordinary share to the holder of
each existing ordinary share, the effect of which will be the
equivalent of a two-for-one stock split.
Following the passing of this resolution, the issue of the new
shares will be made to the holders of record on October 13, 2006.
ICON is a global provider of outsourced development services to
the pharmaceutical, biotechnology and medical device industries. We
specialize in the strategic development, management and analysis of
programs that support clinical development - from compound selection
to Phase I-IV clinical studies. ICON teams have successfully conducted
over 1,900 development projects and over 2,300 consultancy engagements
across all major therapeutic areas. ICON currently has over 3,700
employees, operating from 45 locations in 30 countries. Further
information is available at http://www.iconclinical.com.
The statements made in this Press Release may contain
forward-looking statements that involve a number of risks and
uncertainties. In addition to the matters described in this Press
Release, the ability to maintain large client contracts or enter into
new contracts, maintain client relationships and the ability to manage
the opening of new offices, the integration of new business mergers
and acquisitions, as well as other risks and uncertainties detailed
from time to time in SEC reports filed by ICON, including its Form
20-F, F-1, S-8 and F-3, may affect the actual results achieved by
ICON. ICON disclaims any intent or obligation to update these
forward-looking statements.
Source: ICON plc
